

# INNOVATIVE TECHNOLOGY

The geko™ wound therapy device.

A paradigm shift in the management of wounds

## IMPACT TO THE HEALTHCARE SYSTEM


- Up to 50% of all healthcare and 50% of nursing visits<sup>1,3</sup> in the community involve wound care
- 40% of persons receiving community care have a chronic wound<sup>1,3,4</sup>
- Leg ulcers affect up to 3% of the adult population worldwide and accounts for 60–80% of all cases of ulceration<sup>2</sup>
- The estimated prevalence of active venous ulcers is 1 per 1000 population<sup>2</sup>
- Even after 12 months of care, 20% to 30% will remain unhealed and up to 70% of VLU's will recur within twelve months<sup>2</sup>
- The cost of home care for individuals with leg ulcers (venous stasis ulcers), in Canada, is estimated to be more than \$100 million per year<sup>1</sup>

## WHAT IT IS?


The geko™ device, which is the size of a wristwatch and worn at the knee, gently stimulates the common peroneal nerve with painless electrical pulses. This non-invasive device is fitted to the side of the leg, near the knee it activates the calf-muscle pump returning blood from the lower leg to the heart, in both mobile and immobile patients. It is indicated for the promotion of blood flow, wound healing, the treatment of edema, ischemia, and venous insufficiency.

## BENEFITS OF THE DEVICE?


- The geko™ device is clinically proven to increase venous, arterial and microcirculatory blood flow<sup>7,8</sup> while reducing pain<sup>6</sup> in individuals with lower leg ulcers.
- Microcirculatory red blood cell flux is increased by 225% to the wound bed and 67% to the peri-wound skin in an infected venous ulcer.<sup>9</sup>



Infected ulcer



Increase with heart systole -  
The geko™ device not activated



Increase with the geko™  
device activated

- Accelerated weekly healing rates, and time-to-healing in patients who were adherent to the geko™ and best practices<sup>10,11, 12</sup>
- Reduction in chronic edema<sup>13, 14</sup>
- Improved tolerance to therapeutic levels of compression therapy<sup>10,11,12</sup>
- Decreased length of stay and an estimated cost-savings of \$2,500.00 per patient if used as a first-line adjunctive therapy<sup>15</sup>
- Decreased nociceptive & neuropathic pain<sup>10,11,12,16</sup>

*"I took these pain and narcotic meds all the time, before using the geko™ device, and then during the time the geko™ was on my leg, I was not taking those meds, I was getting healed by the device working, and now after I stopped the device, I am great, I am feeling good"*<sup>16</sup> – Patient

## MORE INFORMATION

**Microcirculatory Flux and Pulsatility in Arterial Leg Ulcers is Increased by Intermittent Neuromuscular Electrostimulation of the Common Peroneal Nerve.** The study concludes that the geko™ device increases microcirculatory blood flow to the wound bed and edge in patients with ischemic lower limb wounds. Click [here](#) to download

**Neuromuscular stimulation of the common peroneal nerve increases arterial and venous velocity in patients with venous leg ulcers:** The study concludes that the geko™ device provides substantial augmentation of venous and arterial flow in the lower limb of patients with venous leg ulcers. Click [here](#) to download.

**Microcirculatory changes in venous leg ulcers using intermittent electrostimulation of common peroneal nerve:** The study concludes that the geko™ device substantially increased both microcirculatory flux and plasticity in the wound bed and in the periwound area in venous leg ulcers. Click [here](#) to download.

